Vortex BioSciences, a portfolio company of AIM-listed IP firm NetScientific PLC(LON:NSCI), has made the first direct commercial sale of its VTX-1 Liquid Biopsy System.
VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis.
The process traps unlabelled CTCs in microscale vortices from whole blood, allowing researchers to better understand cancer progression.
Francois Martelet, Vortex BioSciences’s chairman and NetScientific’s chief executive, said it was an important step towards commercialising VTX.
“The system combines industry-leading purity and high CTC capture rates of between 65%-75%, which we believe can give researchers the opportunity to open new windows into our understanding of cancer.
Gene Walther, Vortex’s chief executive, added: "The reaction to the VTX-1 throughout the marketplace has been unbelievably positive, confirming both the tremendous potential CTCs offer and the unique value of the VTX-1."